Neuro Pace Inc NPCE
Institutional shares held
18.7 Million
28.9K
calls
7.5K
puts
Total value of holdings
$160M
$247K
calls
$64K
puts
Market Cap
$213M
24,846,900
Shares Out.
Institutional ownership
75.42%
# of Institutions
62
We take great care to ensure that the data presented and summarized in this overview for NeuroPace Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NPCE
View all-
Kck Ltd. Tortola, D85.62MShares$48.1 Million77.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA4MShares$34.3 Million1.19% of portfolio
-
Morgan Stanley New York, NY2.48MShares$21.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$20.8 Million2.63% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT778KShares$6.66 Million0.66% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA644KShares$5.51 Million4.05% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny606KShares$5.18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA489KShares$4.18 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA204KShares$1.74 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY140KShares$1.2 Million0.0% of portfolio
Latest Institutional Activity in NPCE
Top Purchases
Top Sells
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Insider Transactions at NPCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,674
-0.14%
|
$65,436
$14.03 P/Share
|
|
May 02
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,842
-0.26%
|
$123,788
$14.01 P/Share
|
|
May 01
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,690
-0.46%
|
$219,660
$14.02 P/Share
|
|
Apr 24
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,781
-0.05%
|
$24,934
$14.06 P/Share
|
|
Apr 23
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,791
-0.63%
|
$305,074
$14.29 P/Share
|
|
Apr 22
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24,609
-0.71%
|
$344,526
$14.05 P/Share
|
|
Apr 19
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,253
-0.52%
|
$255,542
$14.02 P/Share
|
|
Apr 18
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,623
-0.07%
|
$36,722
$14.06 P/Share
|
|
Apr 17
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
300
-0.01%
|
$4,200
$14.15 P/Share
|
|
Apr 16
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
14,069
-0.4%
|
$196,966
$14.01 P/Share
|
|
Apr 12
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,101
-0.65%
|
$323,414
$14.42 P/Share
|
|
Apr 11
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
461,899
-11.54%
|
$6,466,586
$14.49 P/Share
|
|
Feb 27
2024
|
Martha Morrell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+12.16%
|
-
|
|
Feb 27
2024
|
Joel Becker Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,470
+50.0%
|
-
|
|
Feb 27
2024
|
Rebecca Kuhn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+7.59%
|
-
|
|
Feb 05
2024
|
Martha Morrell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,446
-4.24%
|
$51,690
$15.17 P/Share
|
|
Feb 02
2024
|
Martha Morrell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,143
-14.83%
|
$212,145
$15.07 P/Share
|
|
Feb 01
2024
|
Martha Morrell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
663
-0.69%
|
$9,945
$15.04 P/Share
|
|
Jan 31
2024
|
Martha Morrell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,923
-1.96%
|
$28,845
$15.08 P/Share
|
|
Jan 30
2024
|
Martha Morrell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,262
-10.31%
|
$168,930
$15.1 P/Share
|
Last 12 Months Summary
Buy / Acquisition
77.5K
Shares
From
3
Insiders
| Grant, award, or other acquisition | 77.5K shares |
|---|
Sell / Disposition
693K
Shares
From
3
Insiders
| Open market or private sale | 693K shares |
|---|